Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
CytomX Therapeutics, Inc. (CTMX) had Stock-Based Compensation of $2.01M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$50.92M |
|
$23.52M |
|
-- |
|
$50.92M |
|
$28.30M |
|
$22.62M |
|
$0.97M |
|
$23.59M |
|
$23.59M |
|
$23.52M |
|
$23.52M |
|
$23.52M |
|
$23.52M |
|
$22.62M |
|
$22.55M |
|
87.12M |
|
87.15M |
|
$0.27 |
|
$0.27 |
|
| Balance Sheet Financials | |
$86.63M |
|
$2.23M |
|
$11.87M |
|
$98.50M |
|
$50.20M |
|
-- |
|
$23.25M |
|
$73.45M |
|
$25.05M |
|
$23.55M |
|
$25.05M |
|
80.62M |
|
| Cash Flow Statement Financials | |
$-21.04M |
|
$30.60M |
|
-- |
|
$39.08M |
|
$48.63M |
|
$9.55M |
|
|
Stock-Based Compensation |
$2.01M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
44.43% |
|
44.43% |
|
-- |
|
46.32% |
|
46.20% |
|
$-21.16M |
|
-- |
|
-- |
|
-- |
|
0.52 |
|
-- |
|
26.03 |
|
3.46 |
|
93.92% |
|
99.88% |
|
23.88% |
|
93.92% |
|
$0.31 |
|
$-0.24 |
|
$-0.24 |
|